Seagen

SGNTUC-016

NCT03975647

JCP086

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

HER2+

Investigational

Product

Tucatinib

Selective HER2 kinase inhibitor (p.o.)

Treatment Arms

o Experimental: Tucatinib + T-DM1

o Active Comparator: Placebo + T-DM1